A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study - Wikidata - wikimedia - TriplyDB

A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study

A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study

http://www.wikidata.org/entity/Q33406813

about

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways Advances in the management of paediatric high-grade glioma.Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma Molecular profiling of childhood cancer: Biomarkers and novel therapies Advances in paediatric cancer treatment The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines.The rationale for targeted therapies in medulloblastoma.Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.Medulloblastoma development: tumor biology informs treatment decisions Biology and Treatment of Rhabdoid Tumor.Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma.Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update.Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification.Retrospective evaluation of the outcomes of children with diffuse intrinsic pontine glioma treated with radiochemotherapy and valproic acid in a single center.Histone deacetylase inhibitor for NUT midline carcinoma.Characterization of brain tumor initiating cells isolated from an animal model of CNS primitive neuroectodermal tumors.Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule

P2860

Q28550980-8CAF8FCA-DAC3-4BF9-A465-D97C07035D32 Q30870633-184C50D7-9B7C-49C1-94F8-23EE552AA06B Q33420546-86A3163D-BCB5-4A4C-B6AF-048AF52EF67E Q36250783-1D56C5D5-8D5B-45ED-BED8-C0C4D1543FCD Q36508630-74530553-B09F-4A5F-ABE1-C3B5B0507B81 Q36810416-A8D99B6C-D250-47D3-8337-674C2CB9EDDC Q37409736-FBE36B35-127C-463E-8AFD-AC9C32F73CBD Q38139309-A722C6BC-EBDE-4D9C-B356-1C8CF94D7766 Q38376606-BCD06EF8-4476-4F56-B5E6-EB03EFDD60BB Q38582867-6F01EDA7-E339-4743-AB7D-511B6E2794A3 Q39236500-B11B7639-1D3D-4192-BBFB-D3EAAFF3C9F7 Q41728555-568F2941-F97C-420A-83E1-8E9A0669AC4D Q47133403-BA6470E0-8A1C-47CE-A140-A1BBD59DC37F Q47282920-CD0ED027-13C1-42FE-A797-43A8F617A6AD Q47843990-CFA7D374-2FCA-4E19-B5B0-C2C38E32D60B Q48831107-ADE7B0BA-B737-4DA5-B89C-AC16A1C6E194 Q51065495-E7EB6CDC-21BA-4FFF-B462-98873365950B Q52724801-9A255AC9-12A0-47A7-BF01-4E7C4B0633F0 Q57299883-11BCA649-9C55-46F9-8F66-6E85EAD74FF2

P2860

A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study

http://www.wikidata.org/entity/Q33406813

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A pediatric phase 1 trial of v ...... Group phase 1 consortium study

@ast

A pediatric phase 1 trial of v ...... Group phase 1 consortium study

@en

type

label

A pediatric phase 1 trial of v ...... Group phase 1 consortium study

@ast

A pediatric phase 1 trial of v ...... Group phase 1 consortium study

@en

prefLabel

A pediatric phase 1 trial of v ...... Group phase 1 consortium study

@ast

A pediatric phase 1 trial of v ...... Group phase 1 consortium study

@en

P1433

Q33406813-B1EF5E8F-3272-4845-B619-000D09FA94C5

P1476

Q33406813-87979132-F31C-4E86-9CBA-796DC222F3FE

P2093

Q33406813-0FAEEFBA-2ECD-41AC-93DF-3946EC4A9057

Q33406813-23CDF4E6-FF32-4066-967F-84EAD601D9C5

Q33406813-29325298-A0EE-41E2-A6B2-89080910F22B

Q33406813-323CA4A4-A900-41FB-AD96-444362DE29B2

Q33406813-334E50CD-72A2-42E0-B440-7DFE410B4B15

Q33406813-49E08907-2DF8-45C3-8839-FA83EA4AB343

Q33406813-4C1F256E-5AC9-43CE-ACA6-31F394F97352

Q33406813-54F008D8-B762-4734-8C6B-CDE7F927A7F7

Q33406813-7D8CD8FE-DF84-4E12-A978-FE367E459F4B

Q33406813-DEEA6CFC-1C9A-4B50-8466-89801DC1C990

P2860

Q33406813-12582CE4-D624-4E71-95EF-717811E5BE9A

Q33406813-146BA449-7CB0-4D12-8EDB-457DEF8CA2DA

Q33406813-482B891E-A2F4-41E0-8894-812A0D13D97E

Q33406813-4B4F302F-28D6-4E2C-B590-804B613AB936

Q33406813-574D9E3F-9654-4273-ABDA-ED28CE855F24

Q33406813-5AFB3406-9ED7-4F72-AEC1-CCA4132E1703

Q33406813-5B805BF5-7BCB-4266-A20A-E60580E09FEB

Q33406813-5CAA1897-9EC8-4EE8-B345-2B1FB14702D6

Q33406813-61D30B35-C4DA-4D1B-9AEB-89C57F0C7E01

Q33406813-62A736FE-4A81-4ABD-A170-517DA45F406C

P304

Q33406813-311AAC58-6D3F-4F15-81FD-B521C76D9E92

P31

Q33406813-830F7313-960E-4E78-A266-7E2B41DF3B2E

P356

Q33406813-DB511C49-F7EA-43B3-A3C5-78B8AEBC3597

P433

Q33406813-ED9BD08A-4DA1-4786-AE83-13E3DA43DB92

P478

Q33406813-749DE687-70FB-4C58-BF31-7BD4B665F4A5

P50

Q33406813-90B1D76E-51FD-4438-9C0D-585596123A78

Q33406813-9E5F91A6-778F-4C1C-8E44-DBD0D7E908D8

P577

Q33406813-3D1E3DD4-28D9-43F4-B0D9-FC08D8D23CCB

P698

Q33406813-F3D1EE14-4240-4891-B2A0-887D82347307

P921

Q33406813-ED6174F5-F756-41C8-ABBA-C56027677445

P932

Q33406813-81758A3D-2285-4875-B313-323479083D28

P356

P1433

Pediatric Blood & Cancer

P1476

A pediatric phase 1 trial of v ...... Group phase 1 consortium study

@en

P2093

Ashish M Ingle

http://www.w3.org/2001/XMLSchema#string

Brenda Weigel

http://www.w3.org/2001/XMLSchema#string

Charlotte Ahern

http://www.w3.org/2001/XMLSchema#string

Joel M Reid

http://www.w3.org/2001/XMLSchema#string

Lars Wagner

http://www.w3.org/2001/XMLSchema#string

Matthew M Ames

http://www.w3.org/2001/XMLSchema#string

Renee M McGovern

http://www.w3.org/2001/XMLSchema#string

Richard J Gilbertson

http://www.w3.org/2001/XMLSchema#string

Terzah Horton

http://www.w3.org/2001/XMLSchema#string

Trent R Hummel

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

The epigenomics of cancer

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.

Phase II trial of temozolomide in patients with progressive low-grade glioma.

Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas.

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.

Temozolomide in children with progressive low-grade glioma.

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.

P304

1452-1457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.24541

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23554030

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4139006

http://www.w3.org/2001/XMLSchema#string